All In Biotech

NDA 212477 · Gilead Sciences INC

Harvoni

Ledipasvir, Sofosbuvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Aug 28, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

112

24 Phase 3, 0 recruiting

FAERS reports

19,121

7,455 serious, 780 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HARVONI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus...

What it is approved for

From the label in effect Nov 6, 2026.

HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )

Mechanism: HARVONI is a fixed-dose combination of ledipasvir and sofosbuvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 15, 2019 Supplement 2 · Efficacy LetterLabel
  • Aug 28, 2019 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
  • HARVONI · LEDIPASVIR 33.75MG/PACKET; SOFOSBUVIR 150MG/PACKET · PELLETS, ORAL · Prescription
  • HARVONI · LEDIPASVIR 45MG/PACKET; SOFOSBUVIR 200MG/PACKET · PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ledipasvir" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue4,131
  • headache3,707
  • nausea1,242
  • drug ineffective1,140
  • diarrhoea913
  • hepatitis c887
  • insomnia835
  • vomiting442
  • dizziness440
  • drug dose omission436
  • hepatocellular carcinoma402
  • treatment failure374

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20131
2014125
20154,134
20165,147
20174,537
20182,885
20191,344
2020414
2021221
2022160
202368
202434
202524
202626

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Harvoni (Ledipasvir/Sofosbuvir)

2024 spending

$35.9M

Beneficiaries

498

1,174 claims

Per beneficiary

$72,174

$1,073.72 per unit

View as table
YearSpending
2020$243,154,493
2021$143,191,082
2022$77,783,313
2023$54,963,199
2024$35,942,415

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 151 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.